---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-000453"
form_type: "8-K"
ticker: "ZIVO"
cik: "0001101026"
company_name: "Zivo Bioscience, Inc."
filed_at: "2025-01-15T23:59:59+00:00"
generated_at: "2026-05-28T00:49:14.968295+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Zivo Bioscience swaps revenue share obligations for 212,260 shares; director affiliates participate

## Summary
- Company authorized exchange of up to 212,260 shares for cancellation of Participation Agreements with accredited investors.
- To date, completed exchanges with two investors for 14,200 shares of common stock.
- Director Laith Yaldoo manages two entities expected to participate in the Exchange Program.
- Exchange eliminates investor rights to future revenue share cash and a $5.3M buy-out option.
- Investors retain Warrants issued under the original Participation Agreements.

## SEC filing metadata
- accession: 0001654954-25-000453
- form_type: 8-K
- ticker: ZIVO
- cik: 0001101026
- company_name: Zivo Bioscience, Inc.
- filed_at: 2025-01-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1101026/000165495425000453/0001654954-25-000453-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1101026/000165495425000453/zivo_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-000453
- JSON: https://secwatch.observer/filing/0001654954-25-000453.json
- Plain text: https://secwatch.observer/filing/0001654954-25-000453.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.